Dengue Management - Current Guidelines (2025-2026)

Guideline Update: WHO published its new arboviral disease guidelines on July 10, 2025 - the first global guidelines covering dengue, chikungunya, Zika, and yellow fever together. These are now the most current authoritative recommendations.

1. Overview and Epidemiology

2. Clinical Classification (WHO 2009 - Still Standard)

Three-tier Classification

Classic DHF Grading (WHO)

• Park's Textbook of Preventive & Social Medicine, p. 295

Disease Phases

• Febrile phase (days 1-3): High fever, headache, retro-orbital pain, myalgia/arthralgia, facial erythema, maculopapular rash, leukopenia, petechiae
• Critical phase (days 3-7, around defervescence): Plasma leakage lasting 24-48 hours - risk of pleural effusion, ascites, hypovolemic shock, hemorrhage. Rising hematocrit = warning
• Recovery/Convalescent phase: Reabsorption of extravascular fluid, watch for fluid overload (hematocrit falls due to dilution)

3. Diagnosis

Diagnostic Tests - Time-Based Selection

• Red Book 2021, p. 523; Goldman-Cecil Medicine, p. 3657

4. Management

Core Principle: No specific antiviral therapy exists. Management is entirely supportive, stratified by disease severity.

A. Dengue Fever (Without Warning Signs) - Outpatient

1. Oral hydration: ORS, fruit juices, electrolyte-rich fluids to replace losses from fever and vomiting. Goal: urine output at least once every 6 hours
2. Antipyretics: Paracetamol (acetaminophen) only; dose interval should not be less than 6 hours; tepid sponging for high fever
3. STRICTLY AVOID: Aspirin (risk of Reye's syndrome and bleeding), NSAIDs (ibuprofen - aggravate gastritis and bleeding tendency), steroids
4. Monitoring: Daily clinical review; serial hematocrit and platelet counts from day 3
5. Return to hospital immediately if: no improvement, deterioration around defervescence, severe abdominal pain, persistent vomiting, cold clammy extremities, lethargy, any bleeding (black stools, coffee-ground vomitus), no urine output for >4-6 hours

• Park's Textbook, p. 294; Red Book 2021, p. 524

B. Dengue WITH Warning Signs or DHF Grades I-II - Hospitalize

1. IV fluid therapy if unable to tolerate oral fluids or persistent vomiting
2. Use isotonic crystalloids (normal saline, Ringer's lactate) as first-line IV fluid
3. Serial hematocrit monitoring: Rising Hct indicates plasma leakage; guide fluid rate accordingly. If Hct rises ≥20% from baseline = significant leakage
4. Platelet monitoring: Serial counts every 6-12 hours during critical phase
5. Watch for: early shock, occult bleeding, fluid overload, electrolyte disturbances
6. Paracetamol continues for fever; temperature target <39°C
7. Urine output monitoring: Target >0.5 mL/kg/hr

C. Severe Dengue - DHF Grades III/IV (DSS) - ICU Level Care

1. Fluid resuscitation: Immediate crystalloid bolus (10-20 mL/kg over 15-30 minutes in children; guided by clinical status in adults). Reassess frequently.
2. Colloids (e.g., dextran, HES) if refractory shock after initial crystalloid trial
3. Blood products: For significant hemorrhage or refractory shock; packed red cells if active bleeding with low Hb; platelet transfusions for active bleeding with severe thrombocytopenia (not prophylactic at any specific count)
4. Oxygen supplementation as indicated
5. Organ support as required (renal replacement, mechanical ventilation if respiratory failure)
6. Avoid fluid overload: With recovery/reabsorption of leaked fluid, reduce IV fluids promptly; diuretics may be required if overloaded with adequate hemodynamics
7. Steroids: Current evidence is inconclusive and insufficient to recommend - do NOT use routinely
8. Platelet transfusions: Only for active significant bleeding; prophylactic transfusions are not recommended even with very low platelet counts in the absence of bleeding

Early recognition and aggressive supportive care reduces case fatality rate (CFR) from 5-10% to <1%. - Red Book 2021, p. 524; Goldman-Cecil, p. 3658

Fluid Management Algorithm Principles (Park's / WHO)

Patient with suspected severe dengue (Grade III/IV):
│
├─ Give crystalloid bolus (10-20 mL/kg over 15-30 min)
│
├─ Response? ──YES──► Slow to maintenance; monitor closely
│
└─ No response after 2 boluses?
   ├─ Check hematocrit
   │   ├─ Rising Hct → Add colloid
   │   └─ Falling Hct → Suspect bleeding → Blood/blood products
   └─ Monitor for fluid overload continuously

D. Disposition Summary

5. Special Populations

Pregnancy

• Vertical transmission rate ~20% (higher near delivery)
• Supportive treatment (hydration + paracetamol); avoid NSAIDs
• Close fetal monitoring; severe dengue in pregnancy associated with preterm labor and adverse perinatal outcomes
• Creasy & Resnik's Maternal-Fetal Medicine

Children (Pediatric)

• Higher risk of severe disease and DSS
• Weight-based fluid calculations essential
• WHO paediatric drug optimization for dengue meeting held Oct 2025 - see WHO PADO report

6. Vaccines

• Goldman-Cecil Medicine, p. 3658

7. Isolation and Infection Control

• Standard precautions in hospital; attention to bloodborne transmission risk
• Prevent secondary transmission: control Aedes mosquitoes around infected patients
• Patient should use mosquito nets/repellent to prevent mosquito feeding during viremic phase (days 1-5 of fever)

8. Monitoring Parameters During Hospitalization

Summary of Key "Do's and Don'ts"

• Red Book 2021: Report of the Committee on Infectious Diseases, pp. 520-524
• Park's Textbook of Preventive and Social Medicine, pp. 293-297
• Goldman-Cecil Medicine (International Edition), pp. 3656-3659
• Rosen's Emergency Medicine, pp. 2629-2631
• Harrison's Principles of Internal Medicine, 22nd Ed. (2025)
• WHO Guidelines for Clinical Management of Arboviral Diseases: Dengue, Chikungunya, Zika and Yellow Fever (Published July 10, 2025)